KDR and breast carcinoma: Combined CTCE-9908 and docetaxel or anti-VEGFR2 monoclonal antibody treatment in the PyMT breast cancer model also enhanced the anti-tumor and anti-metastatic effect compared to single treatment with anti-VEGFR2 or docetaxel [295].